4D-310 in Adults With Fabry Disease and Cardiac Involvement — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

4D-310 in Adults With Fabry Disease and Cardiac Involvement — Stella

Home/Fabry Disease/

View on ClinicalTrials.gov

Recruiting

Back to Fabry Disease trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(4 sites)

Australia

Royal Melbourne Hospital, Melbourne

Royal Perth Hospital, Perth

Westmead Hospital, Westmead

Taiwan

Taipei Veterans General Hospital, Taipei

Key details

Phase

Early testing / Safety & dosing

Sponsor

4D Molecular Therapeutics

Enrollment target

~18 participants

Started

October 2022

Primary completion

June 2026

Age range

18 Years – 65 Years

Last updated February 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.